×
Vanda Pharmaceuticals EBITDA 2010-2024 | VNDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vanda Pharmaceuticals ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Vanda Pharmaceuticals EBITDA 2010-2024 | VNDA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Vanda Pharmaceuticals ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$231.2B
Amgen (AMGN)
$160B
Gilead Sciences (GILD)
$137.1B
Vertex Pharmaceuticals (VRTX)
$123.3B
Bristol Myers Squibb (BMY)
$113.2B
CSL (CSLLY)
$80.1B
GSK (GSK)
$76.6B
Regeneron Pharmaceuticals (REGN)
$76.1B
Argenex SE (ARGX)
$39.3B
Alnylam Pharmaceuticals (ALNY)
$32.5B
BioNTech SE (BNTX)
$28.3B
BeiGene (ONC)
$23.9B
Biogen (BIIB)
$20.1B
Illumina (ILMN)
$15.4B
Insmed (INSM)
$15B
Genmab (GMAB)
$14.9B
Genmab (GNMSF)
$14.7B
Incyte (INCY)
$13.8B
Intra-Cellular Therapies (ITCI)
$13.7B
BioMarin Pharmaceutical (BMRN)
$13.1B
Moderna (MRNA)
$13B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Sarepta Therapeutics (SRPT)
$10.4B
Bio-Techne Corp (TECH)
$10.4B
Vaxcyte (PCVX)
$10.3B
Exelixis (EXEL)
$9.8B
Ascendis Pharma (ASND)
$9.4B
Exact Sciences (EXAS)
$9.2B
Repligen (RGEN)
$9.1B
Bio-Rad Laboratories (BIO.B)
$8.7B